• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

China CDC Wkly . A COVID-19 T-Cell Response Detection Method Based on a Newly Identified Human CD8 + T Cell Epitope from SARS-CoV-2 - Hubei Provinc

tetano

Editor, Senior Moderator
China CDC Wkly


. 2022 Feb 4;4(5):83-87.
doi: 10.46234/ccdcw2021.258.
A COVID-19 T-Cell Response Detection Method Based on a Newly Identified Human CD8 [SUP]+[/SUP] T Cell Epitope from SARS-CoV-2 - Hubei Province, China, 2021


Jie Zhang[SUP] 1 [/SUP], Dan Lu[SUP] 2 [/SUP], Min Li[SUP] 1 [/SUP], Maoshun Liu[SUP] 3 [/SUP], Sijia Yao[SUP] 3 [/SUP], Jianbo Zhan[SUP] 4 [/SUP], William J Liu[SUP] 1 [/SUP], George F Gao[SUP] 1 2 3 [/SUP]



Affiliations

Abstract

Introduction: Similar to antibody detection, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific T-cell response evaluation is also pivotal among the coronavirus disease 2019 (COVID-19) convalescents and the vaccinated populations. Nucleocapsid (N) protein is one of the main structural proteins of SARS-CoV-2 and can trigger T-cell responses in humans.
Methods: An overlapping peptide pool covering the full length of the N protein was designed, peptides with positive T-cell activating potency in COVID-19 convalescents were screened, and CD8[SUP]+[/SUP] T cell epitopes were further identified. The epitope was used to detect the SARS-CoV-2-specific CD8[SUP]+[/SUP] T cell responses in COVID-19 convalescents based in intracellular cytokine staining and tetramer staining in flow cytometry.
Results: A human leukocyte antigen A (HLA-A)*1101-restricted CD8[SUP]+[/SUP] T cell epitope, which could stimulate the production of IFN-γ via peripheral blood mononuclear cells (PBMCs) of the convalescents was defined, and the tetramer generated with this epitope could detect SARS-CoV-2-specific T cells in the PBMCs of the convalescents. The structural investigation eliminated that the epitope was a typical HLA-A*1101-restricted T-cell epitope which was conserved among all the sarbecoviruses.
Discussion: The newly identified SARS-CoV-2-derived T-cell epitope was helpful to detect the cellular immunity against different sarbecoviruses including SARS-CoV and SARS-CoV-2. This study provided an evaluation method and also a peptide candidate for the research and development of T-cell based vaccine for the virus.

Keywords: COVID-19; T-cell; detection method; epitope.
 
Back
Top Bottom